Medera
Business Services · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
5270 California Ave Ste 300, Irvine, Cal...Phone Number
(626) 333-0561Website
medera.bioRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Medera
Founded by globally renowned scientists and clinicians, and managed by seasoned business executives, Medera capitalizes on the world's first human "mini-Heart" Technology and further extends it to include other mini-Organs to form a unique and comprehensive "mini-Life" Platform for revolutionary disease modelling and drug discovery. Using this pioneering technology platform, the company has developed one of the world's largest gene and cell therapeutic pipelines for cardiovascular diseases, including an extensive catalog of therapeutic vectors and a vast network of clinical sites. Three of the company's clinical trials are expected to enter Phase 2B in 2022/23. InnovationExplore more
Medera Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Medera your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Medera recently announced quarterly report
Product Launch: Get notified when Medera launches new products
Medera, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Medera
Website visits: Recent activity has been detected on your website
Check out if Medera is spiking on competitors!
Check if Medera has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Medera had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Medera has new funding data
Recommended Actions
Reach out to Masked Content who joined Medera as Masked Content
Find more new buyers
Compare Similar Companies to Medera
Compare insights from companies similar to Medera, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Medera is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Medera is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Medera.
Medera Tech Stack
A closer look at the technologies used by Medera
Most Recent Scoops
Project
Product Development, Legal Affairs, Medical Research, Pharmaceuticals, Regulations
Product Launch
Product Launch, Research & Development, Product Management, Medical Research, Pharmaceuticals
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Project
Product Development
Medera News & Media
Medera Expands Scientific Advisory Board with Leading Heart Failure and Cardiopulmonary Physiology Experts to Advance HFpEF Gene Therapy Program
Appointments further strengthen clinical leadership as Medera advances its First-In-Human HFpEF gene therapy program toward key upcoming milestones Appointments further strengthen clinical leadership as Medera advances its First-In-Human HFpEF gene therapy program toward key upcoming milestonesMedera Receives FDA Fast Track Designation for Gene Therapy Targeting Duchenne Muscular Dystrophy-Associated Cardiomyopathy
BOSTON, April 16, 2026 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company developing next-generation cardiovascular therapeutics, and its clinical development division Sardocor, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to AAV-SERCA2a, an investigational gene therapy drug designed to treat cardiomyopathy associated with Duchenne muscular dystrophy (DMD-CM), building on prior human clinical experience wiMedera Announces Completion of Patient Enrollment in Cohort B of MUSIC-HFpEF Phase 1/2a Clinical Trial
BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing next-generation therapeutics, today announced that the final patient has been dosed in Cohort B (high-dose cohort, 4.50×10¹³ viral genomes (vg) per patient) of the ongoing MUSIC-HFpEF Phase 1/2a clinical trial evaluating SRD-002 gene therapy for heart failure with preserved ejection fraction (HFpEF). The patient was successfully tMedera to Participate in Oppenheimer Movers in Rare Disease Summit 2025
BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing next-generation therapeutics, today announced that James Kim, Chief Corporate Officer of Medera, will participate in the Oppenheimer Movers in Rare Disease Summit on Thursday, December 11, 2025, at the Sofitel New York, 45 West 44th Street in New York City.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Medera
Sign Up For FreeTo access detailed company insights
Founded by globally renowned scientists and clinicians, and managed by seasoned business executives, Medera capitalizes on the world's first human "mini-Heart" Technology and further extends it to include other mini-Organs to form a unique and comprehensive "mini-Life" Platform for revolutionary disease modelling and drug discovery. Using this pion... Read More
